Trial Profile
A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions
- Sponsors TARIS Biomedical
- 18 Feb 2023 Results assessing Safety, tolerability, and preliminary efficacy of TAR-200 in patients with intermediate risk non muscle invasive bladder cancer presented at the 2023 Genitourinary Cancers Symposium
- 09 Mar 2020 Status changed from active, no longer recruiting to completed.
- 19 Apr 2018 Status changed from recruiting to active, no longer recruiting.